Health Business Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Health Business Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Alimera Sciences
Alimera Sciences, pSivida Limited Amend Medidur(TM) FA Collaboration Agreement
April 4th, 2008
Alimera Sciences and pSivida Ltd (Nasdaq: PSDV; ASX: PSD; Xetra: PSI) announced that they have amended their license and collaboration agreement relating to Medidur(TM) FA, the companies' Phase III investigative treatment for diabetic macular edema (DME), and other Medidur products. Alimera is increasing its equity in the future profits of Medidur FA from 50 to 80 percent in exchange for consideration of up to approximately $78m to pSivida. Consideration to pSivida includes an up-front payment of $12m, a $25m milestone payment upon FDA approval of Medidur(TM) FA, other payments of up to approximately $21m by September 30, 2012, and assumption of pSivida's research and...
Source: Health Business Week (2008-04-04)
|
